Article
Oncology
Jung-hoon Lee, Ashish Saxena, Giuseppe Giaccone
Summary: Small cell lung cancer (SCLC) is a difficult-to-treat cancer that requires novel therapeutics, preclinical models, and understanding of its resistance mechanisms. Recent advancements have led to the development of new treatments, including molecular subcategorization, immunotherapy, targeted therapy, cellular therapy, and radiation therapy.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Yu Liu, Risheng Huang, Deyao Xie, Xiaoming Lin, Liangcheng Zheng
Summary: ZNF674-AS1 expression is decreased in NSCLC compared to normal tissues, and its downregulation is significantly correlated with advanced TNM stage and decreased overall survival of NSCLC patients. ZNF674-AS1 inhibits NSCLC cell proliferation, colony formation, and tumorigenesis, accompanied by G0/G1 cell cycle arrest, through upregulation of p21 and downregulation of miR-423-3p. This study suggests the therapeutic potential of ZNF674-AS1 in NSCLC treatment.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2021)
Article
Oncology
Miao Li, Yan Rui, Wenjia Peng, Junfeng Hu, Anbang Jiang, Zeyu Yang, Linian Huang
Summary: This study investigated a novel molecular therapeutic target, FIGNL1, for lung cancer and found that its high expression was associated with decreased function and enhanced cell death in lung cancer cells.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Wenfeng Gou, Xiaojun Yu, Shaohua Wu, Hongying Wu, Huajie Chang, Leyuan Chen, Huiqiang Wei, Changfen Bi, Hongxin Ning, Yingliang Wu, Wenbin Hou, Daiying Zuo, Yiliang Li
Summary: This study investigated the impact of AND-1 on the radiosensitivity of non-small cell lung cancer (NSCLC) and found that AND-1 inhibition significantly increased the radiosensitivity of NSCLC cells, likely by regulating the cell cycle and enhancing DNA damage.
Article
Cell Biology
Xiao-Wei Zhang, Lin Li, Wen-Qian Hu, Ming-Ning Hu, Yan Tao, Hui Hu, Xiao-Kang Miao, Wen-Le Yang, Qiong Zhu, Ling-Yun Mou
Summary: This study reveals that G protein-coupled receptor neurokinin-1 (NK1R) is significantly upregulated in lung cancer samples and is associated with advanced clinical stages and poor prognosis. NK1R co-expresses with epidermal growth factor receptor (EGFR) and interacts with it in tumor cells. Activation of NK1R promotes lung cancer cell proliferation and migration through EGFR signaling pathways. Inhibition of NK1R suppresses cell proliferation and migration, and knockdown of NK1R slows down tumor growth. The presence of a selective NK1R antagonist enhances the sensitivity of lung cancer cells to specific drugs.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Agnese Montanino, Anna Manzo, Guido Carillio, Giuliano Palumbo, Giovanna Esposito, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Gerardo Botti, Maria C. Piccirillo, Priscilla Cascetta, Giacomo Pascarella, Carmine La Manna, Nicola Normanno, Alessandro Morabito
Summary: Inhibition of angiogenesis has shown efficacy in treating SCLC, with anlotinib being the only drug that has demonstrated improvement in both overall survival (OS) and progression-free survival (PFS) in Chinese patients. Future challenges include evaluating angiogenesis inhibitors in combination with immune-checkpoint inhibitors and chemotherapy in SCLC patients, as well as identifying predictive biomarkers of response to these agents.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Job-Joris Meijer, Alessandro Leonetti, Giulia Airo, Marcello Tiseo, Christian Rolfo, Elisa Giovannetti, Mahrou Vahabi
Summary: Despite poor prognosis for SCLC patients, immunotherapeutic approaches show potential. Targeting aberrant signaling pathways with new agents has shown promising results, while epigenetic alterations, gene amplifications, and mutations can act as potential biomarkers. Further research and clinical translational studies can help identify specific predictive biomarkers.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Kota Ishioka, Hiroyuki Yasuda, Junko Hamamoto, Hideki Terai, Katsura Emoto, Tae-Jung Kim, Shigemichi Hirose, Takashi Kamatani, Sachiyo Mimaki, Daisuke Arai, Keiko Ohgino, Tetsuo Tani, Keita Masuzawa, Tadashi Manabe, Taro Shinozaki, Akifumi Mitsuishi, Toshiki Ebisudani, Takahiro Fukushima, Mari Ozaki, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki, Morio Nakamura, Takashi Ohtsuka, Hisao Asamura, Katsuya Tsuchihara, Yuichiro Hayashi, Ahmed E. Hegab, Susumu S. Kobayashi, Takashi Kohno, Hideo Watanabe, David M. Ornitz, Tomoko Betsuyaku, Kenzo Soejima, Koichi Fukunaga
Summary: In this study, FGF9 was found to play a crucial role in the transdifferentiation of lung adenocarcinoma to small cell lung cancer. The upregulation of FGF9 was confirmed to induce neuroendocrine differentiation in established human lung adenocarcinoma cells, providing direct evidence for FGF9-mediated SCLC transdifferentiation and proposing the FGF9-FGFR axis as a therapeutic target for transdifferentiated SCLC.
Article
Biochemistry & Molecular Biology
Zhoujun Lin, Yin Li, Xiao Han, Zhenkun Fu, Zhenhuan Tian, Chenggang Li
Summary: This study demonstrates the crucial role of the SPHK1/S1PR3/PBX1 axis in regulating the cell cycle of NSCLC and suggests that targeting SPHK1 may have therapeutic potential in tumor treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Zhihua Teng, Jie Yao, Ling Zhu, Lufeng Zhao, Gang Chen
Summary: This study revealed that ZNF655 is abundantly expressed in NSCLC, and its knockdown can inhibit the malignant behaviors of tumor cells, leading to decreased tumorigenesis. ZNF655 may regulate apoptosis of NSCLC cells through the PI3K/Akt and p53 signaling pathways.
Article
Oncology
Si-Liang Wei, Jing-Jing Ye, Li Sun, Lei Hu, Yuan-Yuan Wei, Da-Wei Zhang, Meng-Meng Xu, Guang-He Fei
Summary: This study identified a novel mechanism involving circKIF20B/miR-615-3p/MEF2A signaling axis in the progression of gefitinib resistance in NSCLC. Downregulation of circKIF20B promotes resistance to gefitinib, while upregulation restores sensitivity. Exosomal circKIF20B may serve as a potential therapeutic target and liquid biopsy candidate in gefitinib-resistant NSCLC.
CANCER CELL INTERNATIONAL
(2023)
Article
Multidisciplinary Sciences
Rebecca Caeser, Christopher Hulton, Emily Costa, Vidushi Durani, Megan Little, Xiaoping Chen, Sam E. Tischfield, Marina Asher, Faruk Erdem Kombak, Shweta S. Chavan, Nisargbhai S. Shah, Metamia Ciampricotti, Elisa de Stanchina, John T. Poirier, Charles M. Rudin, Triparna Sen
Summary: Activation of the mitogenic signaling pathway plays a significant role in lung cancer, particularly in small cell lung cancer. Research suggests that the most common subtype of SCLC, SCLC-A, is selectively sensitive to MAPK activation, potentially inhibiting proliferation through inducing cell cycle arrest and senescence.
Article
Oncology
Xiaoliang Zhao, In-Kyu Kim, Bhaskar Kallakury, Joeffrey J. Chahine, Eiji Iwama, Mariaelena Pierobon, Emanuel Petricoin, Justine N. McCutcheon, Yu-Wen Zhang, Shigeki Umemura, Vincent Chen, Changli Wang, Giuseppe Giaccone
Summary: Research demonstrates that the overexpression of Wee1 plays a crucial role in acquired resistance to Chk1 inhibition in SCLC, while bypass activation of the p38MAPK signaling pathway may also contribute to acquired resistance to Chk1 inhibition.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
David W. W. Shia, WooSuk Choi, Preethi Vijayaraj, Valarie Vuong, Jenna M. M. Sandlin, Michelle M. M. Lu, Adam Aziz, Caliope Marin, Cody J. J. Aros, Chandani Sen, Abdo Durra, Andrew J. J. Lund, Arunima Purkayastha, Tammy M. M. Rickabaugh, Thomas G. G. Graeber, Brigitte N. N. Gomperts
Summary: This study identified PEA3 transcription factors as key mediators of relapse progression in small cell lung cancer (SCLC) and identified a clinically actionable small molecule candidate for delaying relapse of SCLC.
Article
Cell Biology
Hua-Si Zhao, Xiao-Min Tao, Qun Wang, Yuan-Yuan Fang, Hong-Yu Zhang, Hua-Qi Wang, Guo-Jun Zhang
Summary: The study revealed that miR-7160 inhibits NSCLC cell growth and progression by silencing SIX1.
Review
Medicine, Research & Experimental
Weizhuo Lu, Zhiwu Chen, Jiyue Wen
Summary: Ischemic stroke is a common and serious disease, and neuroinflammation plays a crucial role in its progression. Microglia, astrocytes, and infiltrating immune cells are involved in the complicated neuroinflammation cascade, releasing different molecules that affect inflammation. Flavonoids, plant-specific compounds, have shown protective effects against cerebral ischemia injury by modulating the inflammatory responses.
BIOMEDICINE & PHARMACOTHERAPY
(2024)
